At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
In Brief
A Phase 4 clinical trial evaluating Etanercept for Plaque Psoriasis. Completed, enrolled 80 participants across 22 sites.
Detailed Summary
To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionAug 2017
Study CompletionDec 2017
TodayJul 2026
First PostedApr 25, 2016
Enrollment StartMay 18, 2016
Primary CompletionAug 14, 2017
Study CompletionDec 6, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.2 years ago
Interventions
Etanerceptdrug
Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.